Advertisement

Effects of Glycopeptide and Lipopeptide Antibiotics on Granulocyte Function In Vitro

  • F. Schumacher-Perdreau
  • E. Schell-Frederick
  • G. Peters
  • G. Pulverer
Conference paper

Abstract

Vancomycin and the newly developed teicoplanin are glycopeptide antibiotics with high activity against gram-positive bacteria, especially staphylococci and streptococci [8]. LY 146032 is a new cyclic polypeptide antibiotic containing a fatty acid moiety [3]. Similar to vancomycin and teicoplanin, the new cyclic lipopeptide demonstrates excellent activity against a broad range of gram-positive bacteria including methicillin-resistant strains of S. aureus and S. epidermidis [9].

Keywords

Time Trace Fatty Acid Moiety Glycopeptide Antibiotic Opsonized Zymosan Human PMNs 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Borland CDR, Farras WE (1979) Reversible neutropenia from vancomycin. JAMA 242:2392–2393PubMedCrossRefGoogle Scholar
  2. 2.
    Easmon CSF, Cole PJ, Williams AJ, Hastings M (1980) The measurement of opsonic and phagocytic function by luminol-dependent chemiluminescence. J Immunol Methods 41:67–71Google Scholar
  3. 3.
    Eliopoulos GMC, Thauvin B, Gerson RC, Moellering J (1985) In vitro activity and mechanism of action of A 21978Cl, a novel cyclic lipopeptide antibiotic. Antimicrob Agents Chemother 27:357–362PubMedGoogle Scholar
  4. 4.
    Ferrante A, Thong YH (1980) Optimal conditions for simultaneous purification of mononuclear and polymorphonuclear leukocytes from human blood by the hypaque-ficollmethod. J Immunol Methods 36:109–117PubMedCrossRefGoogle Scholar
  5. 5.
    Gopal V, Bisno AL, Silverblatt FJ (1976) Failure of vancomycin treatment in Staphylococcus aureus endocarditis. JAMA 236:1604–1606PubMedCrossRefGoogle Scholar
  6. 6.
    Hook EW III, Johnson WD Jr (1978) Vancomycin therapy of bacterial endocarditis. Am J Med 65:411–415PubMedCrossRefGoogle Scholar
  7. 7.
    Klebanoff SJ, Clark RA (1979) The neutrophil: function and clinical disorders. North-Holland, AmsterdamGoogle Scholar
  8. 8.
    Peters G, Pulverer G (1983) Antibacterial activity of teicomycin (MDL 507), a new glycopeptide antibiotic, in comparison to vancomycin. J Antimicrob Chemother 11:94–95PubMedCrossRefGoogle Scholar
  9. 9.
    Peters G, Schumacher-Perdreau F, Pulverer G (1987) In vitro activity of the new peptolide antibiotic LY 146032 against staphylococci: a comparison with the glycopeptide antibiotics vancomycin and teicoplanin. Eur J Clin Microbiol 6:685PubMedCrossRefGoogle Scholar
  10. 10.
    Schell-Frederick E, Frühling J, van der Auwera Ph, van Laethem Y, Klastersky J (1984) 111Indium-oxine-labelled leucocytes in the diagnosis of localized infection in patients with neoplastic disease. Cancer 54:817–824PubMedCrossRefGoogle Scholar
  11. 11.
    Weitzmann SA, Stossel TP, Desmond M (1978) Drug-induced immunological neutropenia. Lancet 1:1068–1072CrossRefGoogle Scholar
  12. 12.
    West BC (1981) Vancomycin-induced neutropenia. South Med J 74:1255–1256PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1989

Authors and Affiliations

  • F. Schumacher-Perdreau
    • 1
  • E. Schell-Frederick
    • 2
  • G. Peters
    • 1
  • G. Pulverer
    • 2
  1. 1.Institute of HygieneUniversity of KölnKöln 41Federal Republic of Germany
  2. 2.Department of Medicine IUniversity of KölnKöln 41Federal Republic of Germany

Personalised recommendations